Commerzbank AG abandoned its planned sale of Polish subsidiary mBank SA, stating the coronavirus outbreak has made it impossible to attract a worthwhile offer.
“The current market environment, which is marked by the corona crisis, does not allow for an attractive valuation in line with the underlying value of mBank,” Chief Financial Officer Bettina Orlopp said in a statement on Monday, May 11.
Commerzbank’s plan to sell the business was already in doubt before the virus crisis hit, as a first round of bidding drew few potential buyers and no attractive offers, according to people with knowledge of the matter. The German bank later stated its better-than-expected capital ratio gives it enough of a financial cushion to do without an mBank sale.
CEO Martin Zielke also said that he will seek cost cuts that go beyond those announced in September. He recently hired the consultant McKinsey & Co. to review the bank’s business model in a sign that an announcement planned for August may involve more than just an update on savings targets, Bloomberg reported on Friday.
Commerzbank’s decision to sell mBank had long been criticized by investors and analysts, who questioned the plan to divest the bank’s best performing unit to fund the restructuring of less profitable ones.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan